Why the study?
The functional role of FOXC1 in cardiac hypertrophy and its impact on cardiomyocyte hypertrophy and mitochondrial dysfunction remain unclear.
Does FOXC1 knockdown reduce hypertrophic responses and mitochondrial dysfunction in models of cardiac hypertrophy?
Population
TAC-induced cardiac hypertrophy mice and Ang II-induced cardiomyocytes (AC16 cells)
Comparison
FOXC1 knockdown using FOXC1 siRNA vs control
Design
Preclinical experimental study
Key result
FOXC1 knockdown suppressed cardiomyocyte hypertrophy and alleviated mitochondrial dysfunction by regulating the FTO axis in preclinical models.
Authors
Loading...
Hypothesis-generating for FOXC1-FTO targeting in hypertrophy; clinical translation requires prospective human validation.
Does FOXC1 knockdown reduce hypertrophic responses and mitochondrial dysfunction in models of cardiac hypertrophy?
FOXC1 knockdown alleviates cardiomyocyte hypertrophy and mitochondrial dysfunction via the FTO axis, presenting a potential therapeutic target for pathological myocardial hypertrophy.
Kong et al. (2026) studied Cardiac hypertrophy. FOXC1 knockdown vs. Control was evaluated on Cardiomyocyte hypertrophy and mitochondrial dysfunction. FOXC1 knockdown suppressed cardiomyocyte hypertrophy and alleviated mitochondrial dysfunction by regulating the FTO axis in preclinical models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: